Recent Research Funding

Tom Russo, MD.

More than $2 million in annual extramural funding goes to researchers in our division, including Thomas Russo, MD.

Faculty research is supported by extramural funding of more than $2 million annually. The majority of support is derived from national funding agencies such the National Institutes of Health, the Department of Defense and the Veterans Administration.

  • Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannii. Thomas Russo (Principal Investigator). Veterans Administration. $1,359,244. 10/1/2019-9/1/2027.
  • Training the Next Generation of Physician Scientists T35 Training Grant. Timothy Murphy (Principal Investigator). NIAID. $293,309. 9/1/2022-8/1/2027.
  • Mab Passive Vaccination against Acinetobacter baumannii. Thomas Russo (Co-Investigator). NIAID/NIH. $485,053. 9/1/2022-8/1/2027.
  • Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer. Brahm Segal (Principal Investigator). NCI. $3,310,823. 8/1/2022-8/1/2027.
  • Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa. Thomas Russo (Co-Investigator). NIAID/NIH. 5/1/2022-4/1/2027.
  • Clinical and Translational Science Award: Buffalo Clinical and Translational Research Center. Timothy Murphy (Principal Investigator). National Center for Advancing Translational Sciences. $19,101,902. 8/1/2019-12/1/2024.
  • HPV and HIV Co-infection: Clinical, Socio-Behavioral and Microbiome Implications. Jonathan Claus (Co-Principal Investigator). NIH. $900,368. 9/1/2022-9/1/2024.
  • Identification of new or unrecognized virulence genes in hypervirulent Klebsiella pneumoniae and antivirulence genes in classical K. pneumoniae. Thomas Russo (Principal Investigator). NIH. $431,682. 8/1/2020-7/1/2024.
  • Genome Evolution During Bacterial Persistence in the Human Airways in COPD. Timothy Murphy (Principal Investigator). NIAID. $2,653,298. 7/1/2019-6/1/2024.
  • Novel Immunological Biomarkers in Ovarian Cancer Prognosis. Brahm Segal (Principal Investigator). NIH. $3,148,229. 6/1/2015-5/1/2023.
  • A study of various antibiotics against Cutibacterium acnes and Staphylococcus epidermidis in permanent and dissolvable cement beads. John Crane (Co-Principal Investigator). American Shoulder and Elbow Surgeons. $10,000. 5/1/2020-12/1/2022.
  • Mab Passive Vaccination against Acinetobacter baumannii. Thomas Russo (Co-Investigator). NIH. $491,635. 9/1/2017-8/1/2022.
  • DHODH Inhibitors: A Potential New Class of Antimicrobials for Treatment of the Drug Resistant Gram-Negative Bacillus Acinetobacter baumannii. Thomas Russo (Co-Principal Investigator). NIH/NIAID. $981,697. 8/1/2018-8/1/2021.